NLRP3 and gout: The discovery of attenuated activation of the NLRP3 inflammasome in colchicine-treated neutrophils and macrophages in the setting of gout [151,152] has prompted the hypothesis that colchicine can also mitigate cholesterol crystal-induced inflammation (via NLRP3 attenuation) within atherosclerotic plaque and display potential benefits in different cardiovascular diseases [153].